FIREFLY NEUROSCIENCE, INC. (AIFF): Nasdaq/NYSE listing notice — WaveDancer receives Nasdaq deficiency notice for bid price below $1.00

FIREFLY NEUROSCIENCE, INC.

Received Nasdaq letter on Dec 9, 2022, for failing minimum bid price of $1.00 over 30 consecutive days.
Has 180-day compliance period until June 7, 2023, to regain compliance.
Must close at $1.00 for at least ten consecutive business days during Compliance Period.
If not compliant, may get second 180-day period if certain conditions are met.
Company evaluating alternatives; no immediate impact on listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

FIREFLY NEUROSCIENCE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 9, 2022, WaveDancer, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between October 27, 2022 and December 8, 2022, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq’s Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

FIREFLY NEUROSCIENCE, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-028820

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.